Vivoryon Therapeutics N.V. (AMS:VVY)

Netherlands flag Netherlands · Delayed Price · Currency is EUR
1.610
-0.010 (-0.62%)
Sep 29, 2025, 10:28 AM CET
-0.62%
Market Cap42.50M
Revenue (ttm)n/a
Net Income (ttm)-12.48M
Shares Out26.23M
EPS (ttm)-0.48
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,730
Average Volume49,740
Open1.620
Previous Close1.620
Day's Range1.610 - 1.620
52-Week Range1.370 - 3.000
Beta1.96
RSI50.47
Earnings DateSep 9, 2025

About Vivoryon Therapeutics

Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 14
Stock Exchange Euronext Amsterdam
Ticker Symbol VVY
Full Company Profile

Financial Performance

Financial Statements

News

Vivoryon Therapeutics NV (FRA:05Y) (H1 2025) Earnings Call Highlights: Strategic Advances Amid ...

Vivoryon Therapeutics NV (FRA:05Y) (H1 2025) Earnings Call Highlights: Strategic Advances Amid Financial Challenges

24 days ago - GuruFocus

Half Year 2025 Vivoryon Therapeutics NV Earnings Call Transcript

Half Year 2025 Vivoryon Therapeutics NV Earnings Call Transcript

24 days ago - GuruFocus

Vivoryon Therapeutics NV (STU:05Y) Q3 2024 Earnings Call Highlights: Strategic Shifts and ...

Vivoryon Therapeutics NV (STU:05Y) Q3 2024 Earnings Call Highlights: Strategic Shifts and Financial Challenges

10 months ago - GuruFocus

Q3 2024 Vivoryon Therapeutics NV Earnings Call Transcript

Q3 2024 Vivoryon Therapeutics NV Earnings Call Transcript

10 months ago - GuruFocus